Manifold Bio
Tissue-targeted medicines, designed in vivo
About Manifold Bio
Manifold Bio is positioned to be the leading tissue-specific medicines company. We’ve built the first high-throughput in vivo (HTV) discovery engine - combining massively multiplexed in vivo screening and AI-powered design to create targeted biologics. Our engine sculpts pharmacokinetics, biodistribution, and other key properties of biologics directly in living systems, solving previously intractable challenges for tissue-specific delivery.
Manifold Bio website preview
Company facts
- Category
- SaaS
- Funding stage
- Series A
- Total raised
- $0
- Founded
- 2020
- Team size
- 11–50
- HQ
- Boston, United States
- Country
- United States
- Website
- manifold.bio
Frequently asked questions
What does Manifold Bio do?
Manifold Bio is positioned to be the leading tissue-specific medicines company. We’ve built the first high-throughput in vivo (HTV) discovery engine - combining massively multiplexed in vivo screening and AI-powered design to create targeted biologics. Our engine sculpts pharmacokinetics, biodistribution, and other key properties of biologics directly in living systems, solving previously intractable challenges for tissue-specific delivery.
Where is Manifold Bio based?
Manifold Bio is based in Boston, United States, United States.
When was Manifold Bio founded?
Manifold Bio was founded in 2020.
How much has Manifold Bio raised?
Manifold Bio has raised $0 in their Series A round.